75 related articles for article (PubMed ID: 9303488)
21. Cloning and increased expression of an insulin receptor substrate-1-like gene in human hepatocellular carcinoma.
Nishiyama M; Wands JR
Biochem Biophys Res Commun; 1992 Feb; 183(1):280-5. PubMed ID: 1311924
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of insulin receptor substrate-1 and hepatitis Bx genes causes premalignant alterations in the liver.
Longato L; de la Monte S; Kuzushita N; Horimoto M; Rogers AB; Slagle BL; Wands JR
Hepatology; 2009 Jun; 49(6):1935-43. PubMed ID: 19475691
[TBL] [Abstract][Full Text] [Related]
23. Increased activity and expression of MAP kinase in HCC model rats induced by 3'-methyl-4-dimethylamino-azobenzene.
Toyoda M; Hashimoto N; Tokita K; Goldstein BJ; Yokosuka O; Kanatsuka A; Suzuki Y; Saito Y
J Hepatol; 1999 Oct; 31(4):725-33. PubMed ID: 10551398
[TBL] [Abstract][Full Text] [Related]
24. Constitutive over-expression of the insulin receptor substrate-1 causes functional up-regulation of Fas receptor.
Wiedmann M; Tamaki S; Silberman R; de la Monte SM; Cousens L; Wands JR
J Hepatol; 2003 Jun; 38(6):803-10. PubMed ID: 12763374
[TBL] [Abstract][Full Text] [Related]
25. Transgenic overexpression of insulin receptor substrate 1 in hepatocytes enhances hepatocellular proliferation in young mice only.
Mohr L; Banerjee K; Kleinschmidt M; Bartolomé Rodríguez MM; Wands JR
Hepatol Res; 2008 Dec; 38(12):1233-40. PubMed ID: 18631251
[TBL] [Abstract][Full Text] [Related]
26. [Current concepts on gangliosides].
Avrova NF; Obukhova EL
Usp Sovrem Biol; 1975; 79(1):33-47. PubMed ID: 164743
[No Abstract] [Full Text] [Related]
27. Synergistic premalignant effects of chronic ethanol exposure and insulin receptor substrate-1 overexpression in liver.
Longato L; de la Monte S; Califano S; Wands JR
Hepatol Res; 2008 Sep; 38(9):940-53. PubMed ID: 18336544
[TBL] [Abstract][Full Text] [Related]
28. Studies on the localization of heterologous antigenic organ and tumor extracts labelled with fluorescein isothiocyanate.
Stelmachowska A; Peryt B; Harlozińska A
Arch Immunol Ther Exp (Warsz); 1966; 14(1):66-73. PubMed ID: 4288262
[No Abstract] [Full Text] [Related]
29. Expression of insulin receptor substrate-1 in hepatocytes: an investigation using monoclonal antibodies.
Furusaka A; Nishiyama M; Ohkawa K; Yamori T; Tsuruo T; Yonezawa K; Kasuga M; Hayashi S; Tanaka T
Cancer Lett; 1994 Aug; 84(1):85-92. PubMed ID: 8076365
[TBL] [Abstract][Full Text] [Related]
30. Enhanced expression of the protein kinase substrate p36 in human hepatocellular carcinoma.
Frohlich M; Motté P; Galvin K; Takahashi H; Wands J; Ozturk M
Mol Cell Biol; 1990 Jun; 10(6):3216-23. PubMed ID: 2160596
[TBL] [Abstract][Full Text] [Related]
31. Histogenesis and tissue reconstruction of mixed mesodermal tumor.
Ishiwata I; Ishiwata C; Soma M; Nakaguchi T; Ono I; Ishikawa H
Exp Pathol; 1986; 30(1):21-32. PubMed ID: 3019754
[TBL] [Abstract][Full Text] [Related]
32. Meeting at the Crossroad between Obesity and Hepatic Carcinogenesis: Unique Pathophysiological Pathways Raise Expectations for Innovative Therapeutic Approaches.
Arvanitakis K; Papadakos SP; Lekakis V; Koufakis T; Lempesis IG; Papantoniou E; Kalopitas G; Georgakopoulou VE; Stergiou IE; Theocharis S; Germanidis G
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834153
[TBL] [Abstract][Full Text] [Related]
33. Non-alcoholic fatty liver disease and diabetes mellitus as growing aetiologies of hepatocellular carcinoma.
Talamantes S; Lisjak M; Gilglioni EH; Llamoza-Torres CJ; Ramos-Molina B; Gurzov EN
JHEP Rep; 2023 Sep; 5(9):100811. PubMed ID: 37575883
[TBL] [Abstract][Full Text] [Related]
34. Obesity, non-alcoholic fatty liver disease and hepatocellular carcinoma: current status and therapeutic targets.
Chen Y; Wang W; Morgan MP; Robson T; Annett S
Front Endocrinol (Lausanne); 2023; 14():1148934. PubMed ID: 37361533
[TBL] [Abstract][Full Text] [Related]
35. Higher Accumulation of Visceral Adipose Tissue Is an Independent Risk Factor for Hepatocellular Carcinoma among Viral Hepatitis Patients with Non-Cirrhotic Livers.
Imai K; Takai K; Miwa T; Maeda T; Hanai T; Shirakami Y; Suetsugu A; Shimizu M
Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885089
[TBL] [Abstract][Full Text] [Related]
36. Expression and Significance of Insulin Receptor Substrate 1 in Human Hepatocellular Carcinoma.
Gao C; Zhang H; Zhang WS; Fang L
Dis Markers; 2020; 2020():7174062. PubMed ID: 32695243
[TBL] [Abstract][Full Text] [Related]
37. Type 2 diabetes mellitus increases the risk of hepatocellular carcinoma in subjects with chronic hepatitis B virus infection: a meta-analysis and systematic review.
Tan Y; Wei S; Zhang W; Yang J; Yang J; Yan L
Cancer Manag Res; 2019; 11():705-713. PubMed ID: 30679924
[TBL] [Abstract][Full Text] [Related]
38. Increased visceral fat volume raises the risk for recurrence of hepatocellular carcinoma after curative treatment.
Imai K; Takai K; Maeda T; Watanabe S; Hanai T; Suetsugu A; Shiraki M; Shimizu M
Oncotarget; 2018 Mar; 9(18):14058-14067. PubMed ID: 29581826
[TBL] [Abstract][Full Text] [Related]
39. Role of insulin receptor substrates in the progression of hepatocellular carcinoma.
Sakurai Y; Kubota N; Takamoto I; Obata A; Iwamoto M; Hayashi T; Aihara M; Kubota T; Nishihara H; Kadowaki T
Sci Rep; 2017 Jul; 7(1):5387. PubMed ID: 28710407
[TBL] [Abstract][Full Text] [Related]
40. Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease.
Wong CR; Nguyen MH; Lim JK
World J Gastroenterol; 2016 Oct; 22(37):8294-8303. PubMed ID: 27729736
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
